Review Article

Genetic Variability in Susceptibility to Occupational Respiratory Sensitization

Berran Yucesoy and Victor J. Johnson

Toxicology and Molecular Biology Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Morgantown, WV 26505, USA

Correspondence should be addressed to Berran Yucesoy, yab7@cdc.gov

Received 22 February 2011; Accepted 18 April 2011

Academic Editor: Gordon L. Sussman

Copyright © 2011 B. Yucesoy and V. J. Johnson. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Respiratory sensitization can be caused by a variety of substances at workplaces, and the health and economic burden linked to allergic respiratory diseases continues to increase. Although the main factors that affect the onset of the symptoms are the types and intensity of allergen exposure, there is a wide range of interindividual variation in susceptibility to occupational/environmental sensitizers. A number of gene variants have been reported to be associated with various occupational allergic respiratory diseases. Examples of genes include, but are not limited to, genes involved in immune/inflammatory regulation, antioxidant defenses, and fibrotic processes. Most of these variants act in combination with other genes and environmental factors to modify disease progression, severity, or resolution after exposure to allergens. Therefore, understanding the role of genetic variability and the interaction between genetic and environmental/occupational factors provides new insights into disease etiology and may lead to the development of novel preventive and therapeutic strategies. This paper will focus on the current state of knowledge regarding genetic influences on allergic respiratory diseases, with specific emphasis on diisocyanate-induced asthma and chronic beryllium disease.

1. Introduction

Workplace allergens can be categorized as either high or low molecular weight allergens. Low molecular weight (LMW) allergens such as diisocyanates, acid anhydrides, and metallic salts are reactive chemicals with molecular weight less than 1000 kD. They act as haptons and can cause sensitization that may or may not be associated with specific immunoglobulin E (IgE). While some LMW agents such as acid anhydrides, platinum salts, and persulfates stimulate IgE antibodies, many others including isocyanates and glutaraldehyde rarely cause IgE-mediated sensitization [1]. On the other hand, high molecular weight (HMW) protein-derived agents (e.g., proteases, flour, and laboratory animal allergens) cause allergic sensitization through mechanisms mediated by IgE [2]. Early detection of sensitization is very important since sensitized individuals can have life-threatening reactions to future exposures even years after the cessation of exposure. Although the risk of sensitization for individuals with underlying atopy is higher for some exposures (particularly IgE-mediated responses), high prevalence (around 20%) of atopy in the general population indicates that atopy alone is not the determining factor [3]. Although the main factors that affect the onset of the symptoms are the types, duration, and intensity of allergen exposure, host genetic factors can modulate how individuals interact with these agents and induce a shift in the dose-response relationship [4]. Recent genetic epidemiology research focused on common gene variants and identified a number of genetic associations and gene-environment interactions for allergic respiratory diseases. Understanding gene-environment interactions is especially important to improve occupational and public health since environmental/occupational factors that influence genetic risk are modifiable. In this respect, the results of molecular epidemiology studies have the potential to be used in risk evaluation and to help determine more accurate safe occupational exposure levels, thereby contributing to improved protection of workers at high risk. This paper will
summarize the contribution of genetic variability to two important occupational respiratory diseases, diisocyanate-induced asthma (DA) and chronic beryllium disease (CBD).

2. Occupational Asthma Caused by Diisocyanates

Among LMW substances, the diisocyanates are the most frequently reported cause of respiratory sensitization in the workplace. These agents are widely used in polymerization reactions for manufacturing surface coatings, varnishes, paints, urethane foams, insulation, and adhesives. Workers in these industries and workers that use these end products may be influenced by potential adverse health effects of such chemicals. National Occupational Exposure Survey database, National Institute for Occupational Safety and Health (NIOSH), showed that at least 280,000 workers were potentially exposed to some form of isocyanates in the United States alone [5]. Isocyanates are the leading cause of occupational asthma (OA), estimated to cause asthma in 5–10% of chronically exposed workers [6–8]. Despite improved industrial hygiene efforts, new cases of OA continue to occur [9, 10]. The most common isomers used in industry are: the aliphatic agent 1,6-hexamethylene diisocyanate (HDI), used principally as a hardener in spray paints, 4,4-di-phenylmethane diisocyanate (MDI), and toluene diisocyanate (TDI). Early diagnosis of OA leads to favorable clinical outcomes (i.e., less risk of chronic and severe asthma) if affected workers are promptly recognized and removed from harmful exposure [9, 11]. In addition to early case detection, it is also important to more closely monitor the most susceptible workers at a preclinical stage.

Genetic epidemiologic studies have identified a number of susceptibility markers for a variety of asthma phenotypes including OA. Most of these genetic studies were hindered by difficulty in defining asthma, a complex phenotype representing allergic and nonallergic types. This has led to selection of intermediate or quantifiable phenotypes (e.g., airway hyperresponsiveness, lung function, and serum IgE levels) in some association studies. On the other hand, OA is a unique model in that the phenotype can be defined accurately by specific inhalation challenge (SIC) testing often considered the gold standard for diagnosing OA [12]. For this reason, OA is an excellent model for studying gene-environment interactions since the causal agent can be identified with SIC and the lag period between initial exposure and onset of sensitization and clinical symptoms can be followed [13].

Given its immune-inflammatory nature, OA phenotypes are likely associated with specific variants of immune-/inflammatory-related genes. Linkage studies have suggested a variety of candidate genes for asthma and related phenotypes in chromosomal regions 2q14-q32, 5q31-q33, 6p24-p21, 7p15-p14, 11q13-q21, 12q21-q24, 13q12-q14, and 20p13 [14–21]. In particular, variants of interleukin (IL)-4, IL-4RA, IL-13, β-adrenergic receptor (β-AR), tumor necrosis factor (TNF)-α, human leukocyte antigen (HLA)-DRB1, DQB1, the β-subunit of the high-affinity IgE receptor (FceRI), CD14, a disintegrin and a metalloproteinase 33 (ADAM33) genes have been consistently associated with asthma-related phenotypes in independent studies [22, 23]. As in other forms of asthma, inflammatory changes and allergen-specific T-lymphocytes are found in the airways of many patients with OA, along with eosinophils, cytokines, and serum IgE antibodies [24–26]. Thus, similar genetic associations as in immune-mediated asthma might be expected to occur in OA. Although a number of genetic association studies have been conducted on individuals with allergic asthma from environmental causes, there are only limited studies on OA.

The Human Leukocyte Antigen (HLA) class II molecules play a role in the presentation of intracellurally processed peptides to CD4+ T-helper cells. HLA class II molecules are highly polymorphic and the variations in their protein structure may determine the specific epitopes presented to T cells. Therefore, HLA class II molecules are also plausible candidates for controlling specific immunological responses to allergens. Genetic studies investigating the immunopathogenesis of OA have focused on HLA Class II alleles. Bignon et al. demonstrated that HLA DQB1*0503 and the allelic combination DQB1*0201/0301 were associated with susceptibility to DA [27] whereas the DQB1*0501 allele and the DQA1*0101-DQB1*0501-DR1 haplotype were considered protective. Subsequently, Mapp et al. confirmed the association with HLA-DQB1*0503 and reported that the DQA1*0104 allele was increased in DA compared with asymptomatic exposed workers. They also showed “protective” alleles, HLA-DQB1*0501 and DQA1*0101, were increased in asymptomatic exposed workers versus those with DA [19]. In another study, a significantly higher proportion of subjects with DA were found to express the HLA-DQB1*0503-associated aspartic acid at residue 57 [28]. HLA associations with DA were also investigated in a population of Asian workers exposed to diisocyanates but the associations found in European workers were not entirely replicated. The HLA haplotypes DRB1*15-DPB1*05 and HLA DRB1*1501-DQB1*0602-DPB1*0501 were reported as a susceptibility marker for the development of TDI-induced asthma in Koreans [29, 30]. Bernstein et al., investigated association between known SNPs in immune response genes (IL-4Ra, IL-13, and CD14) and DA in a group of exposed workers undergoing SIC testing. The results demonstrated increased frequencies of IL-4Ra 150V allele and combinatorial genotypes of IL4RA (150V), IL-13 (R110Q), and CD14 (C159T) in HDI-exposed workers suggesting an exposure-specific interaction [31]. These findings supported the notion that immune mechanisms play an important role in the pathogenesis of DA.

Since isocyanates are known to cause oxidative injury to respiratory epithelial cells, variations within antioxidant defense genes have been examined in workers with DA [32]. Glutathione, a major antioxidant protein found in the bronchial lining fluid and in respiratory epithelial cells, is likely to serve a protective function by binding with free isocyanate molecules and, thereby, preventing damage to respiratory epithelial cells or intracellular binding to respiratory epithelial proteins or proteins in the bronchial lumen [33]. Piirilä et al. examined polymorphisms of the glutathione S-transferase (GST) genes (GSTM1, GSTM3, GSTP1, and GSTT1) in
workers with DA. GSTM1 null genotype was associated with a 1.89-fold risk of DA. Subjects with GSTM1 null and GSTM3 AA genotypes developed late reaction in the specific bronchial provocation test with disocyanates, individually or in combination [34]. Later, Mapp et al. assessed the GSTP1 gene in TDI-exposed asymptomatic and asthmatic workers [18]. The frequency of the GSTP1 Ile105Val Val/Val genotype was lower in subjects with DA, and was significantly lower among subjects with airway hyperresponsiveness. In another study, the N-acetyltransferase (NAT1) slow acetylator genotype was associated with a 2.5-fold risk of OA among diisocyanate-exposed workers. Interestingly, a far greater 7.77-fold risk of OA was reported among workers exposed to TDI, suggesting an exposure-specific association. In addition, a gene-gene interactive effect was identified in diisocyanate-exposed workers with the combined NAT1 or NAT2 slow acetylator genotypes and GSTM1 null genotype [35]. Broberg et al. investigated the influence of variants in TDI-metabolizing genes on the associations between TDI in air (2,4-TDI and 2,6-TDI) and its metabolites toluene di-amine (2,4-TDA and 2,6-TDA) in plasma and urine. Their results showed that the GSTP1 Ile105Val variant modifies the association between 2,4-TDA in plasma and in urine, supporting the importance of GST system for the metabolism of TDI [36]. Based on the role of neurogenic inflammation in TDI-induced airway hyperresponsiveness, the association between neurokinin-2 receptor (NK2R) gene polymorphisms and TDI-induced asthma was investigated in a Korean population. An association was found between the NK2R 7853GG genotype and increased serum VEGF levels, suggesting that NK2R variants may modulate the airway inflammation conferred by VEGF [37]. Another Korean study investigated the possible role of β2-adrenergic receptor gene (ADRB2) polymorphisms in TDI-induced asthma. The Arg16Gly A>G, Leu134Leu G>A, and Arg175Arg C>A SNPs and haplotype [TTACGC] were found to be associated with specific IgE sensitization in TDI-exposed workers [38]. In another study, genome-wide association was performed to identify susceptibility alleles associated with asthma induced by TDI. The results showed significant association between genetic polymorphisms (rs10762058, rs7088181, rs4378283, and rs1786929) of catenin α3 (CTNNA3) and susceptibility to TDI-induced asthma [39]. The CTNNA3 variants have been suggested to influence TDI-induced asthma risk by increasing epithelial damage and airway inflammation.

3. Chronic Beryllium Disease

Chronic beryllium disease (CBD) is a serious granulomatous lung disease caused by beryllium (Be) exposure in the workplace. CBD continues to occur in industries where Be is manufactured and processed such as aerospace, nuclear, automotive, and electronics. NIOSH estimated that up to 134,000 workers in the United States were exposed to beryllium [40]. Be exposure leads to a cell-mediated hypersensitivity (delayed, type IV) reaction in which Be haptenates native proteins leading to the production of the specific allergen [41]. It is known that accumulation of Be-specific CD4(+) T cells and persistent lung inflammation play a key role in the immunopathogenesis of CBD. Prior to the development of CBD, many exposed workers become sensitized and many of those eventually develop CBD. Approximately 50% of sensitized individuals have CBD at initial clinical evaluation [42]. Be-specific T-cell proliferative responses are detected in the blood of exposed workers using the Be lymphocyte proliferation test (BelPPT) [43, 44]. The BelPPT has been shown to identify approximately 70 to 94% of cases of BeS and CBD and widely used in screening and surveillance of Be-exposed workers [45–47]. Epidemiological studies showed the prevalence rates of BeS and CBD to be between 5–21% and 3–21% among beryllium workers, respectively [48, 49]. The pathologic progression from BeS to CBD is not well understood warranting further research into the pathophysiological mechanisms and susceptibility markers of BeS and CBD. Such efforts will be important for early detection and disease prevention in Be-exposed workers.

A number of molecular epidemiology studies showed that the presence of glutamic acid in position 69 of the B1 chain of the HLA-DPB1 molecule confers an increased risk for both BeS and CBD [41, 50–54]. The HLA-DPB1Glu69 frequency was reported to be between 39–90% in sensitized workers and 53–97% in workers with CBD as compared to 19–48% in nonsensitized workers [41, 50–52, 55–61]. Importantly, studies have demonstrated a dose-dependent effect of HLA-DPB1Glu69 alleles suggesting that Glu69 is a potential marker of disease severity in addition to overall disease risk [41]. Although HLA-DPB1Glu69 is more frequent in individuals with BeS and CBD (73–95%), 30–40% of exposed workers carrying HLA-DPB1Glu69 do not develop CBD or BeS [41, 50, 62]. This suggests that other host and environmental factors likely play key roles in the pathogenesis of CBD. Studies investigating the interaction between the HLA-DPB1 Glu69 and Be exposure showed independent and additive effects of Glu69 carriage and Be exposure in the development of BeS and CBD [58, 63].

Rossman et al. reported that HLA-DQB1*06 and HLA-DRB1*11 alleles occurred more often in individuals with CBD [55]. Maier et al. found that HLA-DRB1*01 and DQB1*05 alleles were less frequent in workers with CBD. They also reported that DRB1*13 and DQB1*06 were associated with CBD in the absence of Glu69 [41]. A recent study showed that the DRβ1E71 allele is a risk factor for both CBD and BeS in the absence of Glu69 and highlighted the importance of interactions between peptides and T cells in the development of CBD [61]. Chemically specific Be-protein interactions were also investigated using a computational approach. Glu69 alleloforms with the greatest negative surface charge were found to confer the highest risk for CBD and irrespective of allele, equal risk for BeS [64]. Current HLA research includes investigating whether the risk is associated with any or only certain Glu69 alleles or allelic combinations.

Non-HLA genetic studies also identified some significant associations. Sato et al. investigated eight SNPs within CCR5 gene that is implicated in the chemotaxis and activation of leukocyte subsets. The results showed that CCR5-5663 and -3458 variants were associated with worsening pulmonary
4 Journal of Allergy

Table 1: Examples of genetic associations for DA and CBD.

| Disease | Gene  | Variation | RR; P value; OR (95% CI) | Reference |
|---------|-------|-----------|--------------------------|-----------|
| DA      | HLA-DQB1 | *0503     | RR = 9.8, P < .04         | [27]       |
|         | HLA-DQB1 | *0501     | RR = 0.14, P < .03        | [27]       |
|         | HLA-DQA1 | *0104     | P = .008                 | [19]       |
|         | HLA-DRB1-DPB1 | *15*05 | P = .001                 | [29]       |
|         | GSTM1    | Null      | 1.89 (1.01–3.52)         | [34]       |
|         | NAT1     | Slow acetylator | 7.77 (1.18–51.6) | [35]   |
|         | IL4RA, IL-13 R, CD14 | I50V-R110Q-C159T | 6.4 (1.57–26.12) | [31] |
|         | CTNNA3   | rs1786929 | P = .015                 | [39]       |
| CBD     | HLA-DPB1 | Glu69     | 9.4 (5.4–16.6)           | [50]       |
|         | HLA-DQB1 | G86       | P < .04                  | [55]       |
|         | HLA-DRB1 | S11       | P < .03                  | [55]       |
|         | CCR5     | -3458     | P < .0001                | [65]       |
|         | TGFβ1    | -509      | P = .01                  | [66]       |
|         | GCLC     | TNR 7/7   | 0.28 (0.08–0.95)         | [67]       |
|         | GCLM     | -588 C/C  | 3.07 (1.00–9.37)         | [67]       |
|         | IL-1A    | -1142     | 3.02 (1.36–6.70)         | [69]       |
|         |          | -3769     | 2.51 (1.21–5.19)         | [69]       |
|         |          | -4697     | 2.56 (1.24–5.29)         | [69]       |

RR: relative risk; OR: odds ratio.

function over time in CBD [65]. The -509C and codon 10T variants of the transforming growth factor-β1 (TGFβ) gene, a cytokine with a major role in the fibrotic/Th1 response, were found to be associated with more severe granulomatous disease in CBD [66]. Since glutathione has been reported to be increased in CBD, genetic variants of the glutamate cysteine ligase (GCL), a rate-limiting enzyme in GSH synthesis, were investigated. GCL consists of a catalytic subunit (GCLC) and modifier subunit (GCLM). GCLC trinucleotide repeat polymorphism (7/7 genotype) and the GCLM-588 SNP were found to be associated with altered susceptibility to CBD [67]. While Saltini et al. reported an association between the TNFα-308*02 variant and BeS and CBD, this result was not confirmed in a large population-based study [57, 68]. A recent study showed that IL-1α-1142, -3769, and -4697 variants were significantly associated with CBD compared to individuals with BeS or nonsensitized workers after adjusting for Glu69 status [69]. These results suggested that the formation of granulomas in CBD may require an independent inflammatory response controlled by genes unrelated to beryllium recognition. Table 1 lists some examples of associations found for both DA and CBD.

4. Conclusions

Genetic association studies can provide more accurate information on the interindividual variability, thereby contributing to establishment of more accurate exposure limits in the workplace. These efforts, in a larger perspective, provide opportunities to effectively target engineering controls, personal protective equipment, and intervention strategies to protect the health of high-risk workers. With the advances in high-throughput technologies and computational methodologies, this information could be used in designing better predictive models to incorporate genetic variability into risk evaluation and improving the regulation and redefinition of acceptable exposure levels in the workplace. Success of such approaches depends on how molecular epidemiology studies overcome some of the current challenges. Despite the rapid growth of published associations, some of the genetic associations lack consistency across different studies. The inconsistency in results might be explained by the differences in study populations, phenotype characterization, exposure assessment, characterization of other environmental exposure (e.g., air pollution, smoking), intermediate phenotypes (e.g., airway hyperresponsiveness), statistical inconsistencies and other potentially modifiable risk factors such as lifestyle. For example, allele/carrier frequencies of the HLA-DPB1Glu69 ranged between 0.21/0.38 to 0.33/0.59 across different ethnic populations [70]. This emphasizes the importance of replication studies in independent populations with a different genetic background. Although the genetics of allergic respiratory diseases including DA and CBD have yet to be fully characterized, summarized discoveries hold promise for the identification of susceptibility profiles and characterization of gene-environment interactions. It is to be hoped that future genetic association studies with large, well-characterized populations through national and international collaborations will increase the understanding of the pathogenesis of these diseases and help identify novel therapeutic targets and preventative/educational strategies for better identification and management of occupational diseases.
References

[1] P. Maestrelli, P. Boschetto, L. M. Fabbri, and C. E. Mapp, “Mechanisms of occupational asthma,” Journal of Allergy and Clinical Immunology, vol. 123, no. 3, pp. 531–542, 2009.

[2] E. Meijer, D. E. Grobbee, and D. Heederik, “Detection of workers sensitised to high molecular weight allergens: a diagnostic study in laboratory animal workers,” Occupational and Environmental Medicine, vol. 59, no. 3, pp. 189–195, 2002.

[3] M. Chan-Yeung, “Occupational asthma,” The New England Journal of Medicine, vol. 333, pp. 107–112, 1995.

[4] S. N. Kelada, D. L. Eaton, S. S. Wang, N. R. Rothman, and M. J. Khoury, “The role of genetic polymorphisms in environmental health,” Environmental Health Perspectives, vol. 111, no. 8, pp. 1055–1064, 2003.

[5] NIOSH, National Occupational Exposure Survey (NOES), 1981–1983, 1983.

[6] C. A. Redlich and M. H. Karol, “Diisocyanate asthma: clinical aspects and immunopathogenesis,” International Immunopharmacology, vol. 2, no. 2, pp. 213–224, 2002.

[7] J. A. Bernstein, “Overview of diisocyanate occupational asthma,” Toxicology, vol. 111, pp. 181–189, 1996.

[8] K. Rydzynski and C. Palczynski, “Occupational allergy as a challenge to developing countries,” Toxicology, vol. 198, pp. 1–3, pp. 75–82, 2004.

[9] D. I. Bernstein, L. Korbee, T. Stauer et al., “The low prevalence of occupational asthma and antibody-dependent sensitization to diphenylmethane diisocyanate in a plant engineered for minimal exposure to diisocyanates,” Journal of Allergy and Clinical Immunology, vol. 92, no. 3, pp. 387–396, 1993.

[10] M. L. Wang and E. L. Petsonk, “Symptom onset in the first 2 years of employment at a wood products plant using diisocyanates: some observations relevant to occupational medical screening,” American Journal of Industrial Medicine, vol. 46, no. 3, pp. 226–233, 2004.

[11] S. M. Tarlo, D. Banks, G. Liss, and I. Broder, “Outcome determinants for isocyanate induced occupational asthma among compensation claimants,” Occupational and Environmental Medicine, vol. 54, no. 10, pp. 756–761, 1997.

[12] H. G. Ortega, D. N. Weissman, D. L. Carter, and D. Banks, “Use of specific inhalation challenge in the evaluation of workers at risk for occupational asthma: a survey of pulmonary, allergy, and occupational medicine residency training programs in the United States and Canada,” Chest, vol. 121, no. 4, pp. 1323–1328, 2002.

[13] A. J. Frew, “What can we learn about asthma from studying occupational asthma?” Annals of Allergy, Asthma and Immunology, vol. 90, no. 5, pp. 7–10, 2003.

[14] Y. Zhang, N. I. Leaves, G. G. Anderson et al., “Positional cloning of a quantitative trait locus on chromosome 13q14 that influences immunoglobulin E levels and asthma,” Nature Genetics, vol. 34, no. 2, pp. 181–186, 2003.

[15] M. Allen, A. Heinzmann, E. Noguchi et al., “Positional cloning of a novel gene influencing asthma from Chromosome 2q14,” Nature Genetics, vol. 35, no. 3, pp. 258–263, 2003.

[16] P. Van Eerdewegh, R. D. Little, J. Dupuis et al., “Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness,” Nature, vol. 418, no. 6896, pp. 426–430, 2002.

[17] T. Laitinen, A. Polvi, P. Rydman et al., “Characterization of a common susceptibility locus for asthma-related traits,” Science, vol. 304, no. 5668, pp. 300–304, 2004.

[18] C. E. Mapp, A. A. Fryer, N. D. Marzo et al., “Glutathione S-transferase GSTP1 is a susceptibility gene for occupational asthma induced by isocyanates,” Journal of Allergy and Clinical Immunology, vol. 109, no. 5, pp. 867–872, 2002.

[19] C. E. Mapp, B. Beghè, A. Balboni et al., “Association between HLA genes and susceptibility to toluene diisocyanate-induced asthma,” Clinical and Experimental Allergy, vol. 30, no. 5, pp. 651–656, 2000.

[20] Z. Wang, C. Chen, T. Niu et al., “Association of asthma with β-adrenergic receptor gene polymorphism and cigarette smoking,” American Journal of Respiratory and Critical Care Medicine, vol. 163, no. 6, pp. 1404–1409, 2001.

[21] C. Brasch-Andersen, Q. Tan, A. D. Berglum et al., “Significant linkage to chromosome 12q24.32-q24.33 and identification of SFRS8 as a possible asthma susceptibility gene,” Thorax, vol. 61, no. 10, pp. 874–879, 2006.

[22] C. Ober and S. Hoffjan, “Asthma genetics 2006: the long and winding road to gene discovery,” Genes and Immunity, vol. 7, no. 2, pp. 95–100, 2006.

[23] C. E. Mapp, “The role of genetic factors in occupational asthma,” European Respiratory Journal, vol. 22, no. 1, pp. 173–178, 2003.

[24] A. M. Bentley, P. Maestrelli, M. Saetta et al., “Activated T-lymphocytes and eosinophils in the bronchial mucosa in isocyanate-induced asthma,” Journal of Allergy and Clinical Immunology, vol. 89, no. 4, pp. 821–829, 1992.

[25] H. S. Park, H. Y. Kim, D. H. Nahm, J. W. Son, and Y. Y. Kim, “Specific IgG, but not specific IgE, antibodies to toluene diisocyanate-human serum albumin conjugate are associated with toluene diisocyanate bronchoprovocation test results,” Journal of Allergy and Clinical Immunology, vol. 104, no. 4, pp. 847–851, 1999.

[26] J. L. Malo and M. Chan-Yeung, “Occupational asthma,” Journal of Allergy and Clinical Immunology, vol. 108, no. 3, pp. 317–328, 2001.

[27] J. S. Bignon, Y. Aron, . Li Ya Ju et al., “HLA Class II alleles in isocyanate-induced asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 149, no. 1, pp. 71–75, 1994.

[28] A. Balboni, O. P. Baricordi, L. M. Fabbri, E. Gandini, A. Ciaccia, and C. E. Mapp, “Association between toluene diisocyanate-induced asthma and DQB1 markers: a possible role for aspartic acid at position 57,” European Respiratory Journal, vol. 9, no. 2, pp. 207–210, 1996.

[29] S. H. Kim, H. B. Oh, K. W. Lee et al., “HLA DRB1*15-DPB1*05 haplotype: a susceptible gene marker for isocyanate-induced occupational asthma?” Allergy, vol. 61, no. 7, pp. 891–894, 2006.

[30] J. H. Choi, K. W. Lee, C. W. Kim et al., “The HLA DRB1*1501-DQB1*0602-DPB1*0501 haplotype is a risk factor for toluene diisocyanate-induced occupational asthma,” International Archives of Allergy and Immunology, vol. 150, no. 2, pp. 156–163, 2009.

[31] D. I. Bernstein, N. Wang, P. Campo et al., “Diisocyanate asthma and gene-environment interactions with IL4RA, CD14 and IL-13 genes,” Annals of Allergy, Asthma and Immunology, vol. 89, no. 6, pp. 808–806, 2002.

[32] A. V. Wisnewski, Q. Liu, J. Liu, and C. A. Redlich, “Glutathione protects human airway proteins and epithelial cells from isocyanates,” Clinical and Experimental Allergy, vol. 35, no. 3, pp. 352–357, 2005.

[33] R. C. Lantz, R. Lemus, R. W. Lange, and M. H. Karol, “Rapid reduction of intracellular glutathione in human bronchial epithelial cells exposed to occupational levels of Toluene
diisocyanate,” *Toxicological Sciences*, vol. 60, no. 2, pp. 348–355, 2001.

[34] P. Piiriilä, H. Wikman, R. Luukkonen et al., “Glutathione S-transferase genotypes and allergic responses to diisocyanate exposure,” *Pharmacogenetics*, vol. 11, no. 5, pp. 437–445, 2001.

[35] H. Wikman, P. Piiriilä, C. Rosenberg et al., “N-acetyltransferase genotypes as modifiers of diisocyanate exposure-associated asthma risk,” *Pharmacogenetics*, vol. 12, no. 3, pp. 227–233, 2002.

[36] K. E. Broberg, M. Warholm, H. Tinnerberg et al., “The GSTP1 Ile105 Val polymorphism modifies the metabolism of toluene diisocyanate,” *Pharmacogenetics and Genomics*, vol. 20, no. 2, pp. 104–111, 2010.

[37] Y. M. Ye, Y. M. Kang, S. H. Kim et al., “Relationship between neurokinin 2 receptor gene polymorphisms and serum vascular endothelial growth factor levels in patients with toluene diisocyanate-induced asthma,” *Clinical and Experimental Allergy*, vol. 36, no. 9, pp. 1153–1160, 2006.

[38] Y. M. Ye, Y. M. Kang, S. H. Kim et al., “Probable role of beta 2-adrenergic receptor gene haplotype in toluene diisocyanate-induced asthma,” *Allergy, Asthma and Immunology Research*, vol. 2, no. 4, pp. 260–266, 2010.

[39] S. H. Kim, B. Y. Cho, C. S. Park et al., “Alpha-T-catenin (CTNNA3) gene was identified as a risk variant for toluene diisocyanate-induced asthma by genome-wide association analysis,” *Clinical and Experimental Allergy*, vol. 39, no. 2, pp. 203–212, 2009.

[40] P. K. Henneberger, S. K. Goe, W. E. Miller, B. Doney, and D. W. Groce, “Industries in the United States with airborne beryllium exposure and estimates of the number of current workers potentially exposed,” *Journal of Occupational and Environmental Hygiene*, vol. 1, no. 10, pp. 648–659, 2004.

[41] L. A. Maier, D. S. McGrath, H. Sato et al., “Influence of MHC CLASS II in susceptibility to beryllium sensitization and chronic beryllium disease,” *Journal of Immunology*, vol. 171, no. 12, pp. 6910–6918, 2003.

[42] L. S. Newman, M. M. Mroz, R. Balkissoon, and L. A. Maier, “Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk,” *American Journal of Respiratory and Critical Care Medicine*, vol. 171, no. 1, pp. 54–60, 2005.

[43] K. Kreiss, S. Wasserman, M. M. Mroz, and L. S. Newman, “Beryllium disease screening in the ceramics industry: blood lymphocyte test performance and exposure-disease relations,” *Journal of Occupational Medicine*, vol. 35, no. 3, pp. 267–274, 1993.

[44] L. S. Newman, “Significance of the blood beryllium lymphocyte proliferation test,” *Environmental Health Perspectives*, vol. 104, no. 5, pp. 953–956, 1996.

[45] K. Kreiss, M. M. Mroz, B. Zhen, J. W. Martyny, and L. S. Newman, “Epidemiology of beryllium sensitization and disease in nuclear workers,” *American Review of Respiratory Disease*, vol. 148, no. 4, pp. 985–991, 1993.

[46] M. M. Mroz, K. Kreiss, D. C. Lezotte, P. A. Campbell, and L. S. Newman, “Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease,” *Journal of Allergy and Clinical Immunology*, vol. 88, no. 1, pp. 54–60, 1991.

[47] K. Kreiss, F. Miller, L. S. Newman, E. A. Ojo-Amaize, M. D. Rossman, and C. Saltini, “Chronic beryllium disease—from the workplace to cellular immunology, molecular immunogenetics, and back,” *Clinical Immunology and Immunopathology*, vol. 71, no. 2, pp. 123–129, 1994.
chronic beryllium disease in the nuclear weapons industry,” Occupational and Environmental Medicine. In press.

[64] J. A. Snyder, E. Demchuk, E. C. McCanlies et al., “Impact of negatively charged patches on the surface of MHC class II antigen-presenting proteins on risk of chronic beryllium disease,” Journal of the Royal Society Interface, vol. 5, no. 24, pp. 749–758, 2008.

[65] H. Sato, L. Silveira, P. Spagnolo et al., “CC chemokine receptor 5 gene polymorphisms in beryllium disease,” European Respiratory Journal, vol. 36, no. 2, pp. 331–338, 2010.

[66] A. C. Jonth, L. Silveira, T. E. Fingerlin et al., “TGF-β 1 variants in chronic beryllium disease and sarcoidosis,” Journal of Immunology, vol. 179, no. 6, pp. 4255–4262, 2007.

[67] L. M. Bekris, H. M. A. Viernes, F. M. Farin, L. A. Maier, T. J. Kavanagh, and T. K. Takaro, “Chronic beryllium disease and glutathione biosynthesis genes,” Journal of Occupational and Environmental Medicine, vol. 48, no. 6, pp. 599–606, 2006.

[68] E. C. McCanlies, C. R. Schuler, K. Kreiss, B. L. Frye, J. S. Ensey, and A. Weston, “TNF-α polymorphisms in chronic beryllium disease and beryllium sensitization,” Journal of Occupational and Environmental Medicine, vol. 49, no. 4, pp. 446–452, 2007.

[69] E. C. McCanlies, B. Yucsey, A. Mnatsakanova et al., “Association between IL-1A single nucleotide polymorphisms and chronic beryllium disease and beryllium sensitization,” Journal of Occupational and Environmental Medicine, vol. 52, pp. 680–684, 2010.

[70] A. Weston, J. Ensey, K. Kreiss, C. Keshava, and E. McCanlies, “Racial differences in prevalence of a supratypic HLA-genetic marker immaterial to pre-employment testing for susceptibility to chronic beryllium disease,” American Journal of Industrial Medicine, vol. 41, no. 6, pp. 457–465, 2002.